Synvista Therapeutics logo

Synvista Therapeutics(OTC) SYNI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Synvista Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-09
Synvista Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-13
1 month+0%USD 0.002026-06-05
3 month+0%USD 0.002026-06-05
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-08-14
3 year-99%USD 0.002023-08-24
5 year-99.5%USD 0.002021-09-03
Since inception-100%USD 1,437.501991-11-01

Synvista Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

11.28 (High)

Price

$0.00

Volume

8

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2025

SYNI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Synvista Therapeutics

Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tools and therapeutic drugs for diabetic patients at risk of cardiovascular disease. The company is advancing innovative treatments and diagnostics to improve patient outcomes in this critical healthcare area.

Products and Services
  • ALT-2074, a glutathione peroxidase mimetic in Phase II trials
  • Alagebrium chloride, targeting diastolic heart failure and diabetic nephropathy
  • A diagnostic test for detecting cardiovascular risks in diabetic patients
Growth Outlook
  • Continued advancement of Phase II clinical trials for key products
  • Focus on expanding treatment options for diabetic cardiovascular complications
  • Potential market growth driven by increasing diabetes prevalence
Financial Highlights
  • Market capitalization stands at $3 million, indicating growth potential
  • Recent trading volume reached 5,229 shares, reflecting investor interest
  • Stock price remains stable at $0.000001, with no significant fluctuations
Synvista Therapeutics, Inc. operates in the healthcare sector, specifically within the medical-pharmaceutical industry. The company is dedicated to addressing the needs of diabetic patients, particularly those at risk for cardiovascular issues. With a focused product pipeline and ongoing clinical trials, Synvista aims to make significant contributions to the treatment landscape for diabetes-related complications. The company's commitment to innovation and patient care positions it as a noteworthy entity in the biopharmaceutical field.
AI Generated • Sep 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Parsippany, US

SYNI Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.59M

Volume

8

Avg. Volume

0.492

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Synvista Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.39-4.76%
NVDANvidia
$221.30-3.16%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About SYNI

What is the current price of Synvista Therapeutics?

Synvista Therapeutics is trading at $0.00 per share.

What is the 52-week range for Synvista Therapeutics?

Over the past 52 weeks, Synvista Therapeutics has traded between $0.00 and $0.00.

How much debt does Synvista Therapeutics have?

Synvista Therapeutics total debt is unavailable.

How much cash does Synvista Therapeutics have on hand?

Synvista Therapeutics does not have cash on hand data available.

What is Synvista Therapeutics’s dividend yield?

Synvista Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services